title: Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.
abstract: Glucose transporters (GLUTs) at the blood-brain barrier maintain the continuous high glucose and energy demands of the brain. They also act as therapeutic targets and provide routes of entry for drug delivery to the brain and central nervous system for treatment of neurological and neurovascular conditions and brain tumours. This article first describes the distribution, function and regulation of glucose transporters at the blood-brain barrier, the major ones being the sodium-independent facilitative transporters GLUT1 and GLUT3. Other GLUTs and sodium-dependent transporters (SGLTs) have also been identified at lower levels and under various physiological conditions. It then considers the effects on glucose transporter expression and distribution of hypoglycemia and hyperglycemia associated with diabetes and oxygen/glucose deprivation associated with cerebral ischemia. A reduction in glucose transporters at the blood-brain barrier that occurs before the onset of the main pathophysiological changes and symptoms of Alzheimer's disease is a potential causative effect in the vascular hypothesis of the disease. Mutations in glucose transporters, notably those identified in GLUT1 deficiency syndrome, and some recreational drug compounds also alter the expression and/or activity of glucose transporters at the blood-brain barrier. Approaches for drug delivery across the blood-brain barrier include the pro-drug strategy whereby drug molecules are conjugated to glucose transporter substrates or encapsulated in nano-enabled delivery systems (e.g. liposomes, micelles, nanoparticles) that are functionalised to target glucose transporters. Finally, the continuous development of blood-brain barrier in vitro models is important for studying glucose transporter function, effects of disease conditions and interactions with drugs and xenobiotics.
authors.affiliation: Astbury Centre for Structural Molecular Biology and School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK. s.g.patching@leeds.ac.uk.
authors.forename: Simon G
authors.initials: SG
authors.lastname: Patching
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D051246:Glucose Transport Proteins, Facilitative / Q000502:physiology*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000378:metabolism; D007003:Hypoglycemia / Q000188:drug therapy / Q000378:metabolism; D011355:Prodrugs / Q000008:administration & dosage / Q000378:metabolism*
chemical_list: D051246:Glucose Transport Proteins, Facilitative; D011355:Prodrugs
keywords: Alzheimer’s disease; Blood-brain barrier; Diabetes; Drug delivery; GLUT1; Glucose transporters; In vitro models; Neurological and neurovascular disorders